POLQ and breast carcinoma: Moreover, approximately 30% of ductal carcinoma and lobular carcinoma breast cancers have genetic alterations in synthetic lethality POLQ gene partners and show enhanced Pol θ/TMEJ activity, thereby suggesting that Pol θ inhibition is a promising therapeutic strategy [57].